ISSN 1308-7649 | E-ISSN 2148-3817
Original Article
A Pilot Study Using Intratympanic Methylprednisolone for Treatment of Persistent Posterior Canal Benign Paroxysmal Positional Vertigo
1 Department of Otorhinolaryngology, Hospital de Cabueñes, Gijón, Spain  
2 Department of Otorhinolaryngology, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain  
3 Department of Otorhinolaryngology, Hospital Costa del Sol, Marbella, Spain  
4 Department of Genomic Medicine, GENYO - for Genomics and Oncological Research- Pfizer/University of Granada, Otology and Neurotology Gropu, Granada, Spain  
J Int Adv Otol 2016; 12: 321-325
DOI: 10.5152/iao.2016.3014
Key Words: Benign paroxysmal positional vertigo, intratympanic injection, methylprednisolone

OBJECTIVE: To assess the effect of intratympanic methylprednisolone (ITMP) in posterior canal benign paroxysmal positional vertigo (BPPV) that fails treatment involving repositioning maneuver in a case series.


MATERIALS and METHODS: Nine patients with persistent posterior canal BPPV after 6 or more repositioning maneuvers were treated by ITMP (two weekly doses of 0.3–0.4 mL at 40 mg/mL) before repeating the repositioning procedures.


RESULTS: Following ITMP treatment, 7 out of 9 patients were relieved of their symptoms and did not exhibit positional nystagmus after 1 or 2 repositioning maneuvers. The number of positional maneuvers performed before and after ITMP treatment in these 7 patients showed a statistically significant (p=0.016) reduction in the amount of repositioning treatments required. None of the 7 respondent patients showed any relapses during the follow-up period (follow-up range: 11–95 months).


CONCLUSION: Administering ITMP before resuming repositioning procedures can be a useful treatment for persistent BPPV of the posterior canal.

Key Words
Author's Corner
Reviewer's Corner
AVES | Copyright © 2019 The European Academy of Otology and Neurotology | Latest Update: 15.08.2019